

PharmaMar to Present at the Upcoming Virtual European Biotech Investor Day 2020

Madrid, June 23rd, 2020.- PharmaMar (MSE:PHM) has announced today announced that the management of the company will present an overview of the company and provide a business update at the upcoming Virtual European Biotech Investor Day 2020 hosted by Solebury Trout, Goodwin, Deutsche Bank and Nasdaq. During the presentation, participants will be able to submit questions electronically with answers provided at the discretion of the company on an individual basis afterwards.

Details are as follows:

- Thursday June 25th, at 10:30 a.m. EDT (16:30 CET)
- To access the presentation, please login [HERE](https://www.webcaster4.com/Webcast/Page/2408/35383):
<https://www.webcaster4.com/Webcast/Page/2408/35383>
- Archive of the event will be available on the Company's website at www.pharmamar.com or visiting the [Events Calendar](#) of PharmaMar's website.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno– Capital Markets & Investor Relations Director

María Marín de la Plaza – Capital Markets & Investor Relations

investorrelations@pharmamar.com

Phone: +34 914444500



Or please visit our website at www.pharmamar.com